Vas Narasimhan
Vas Narasimhan is the Chief Executive Officer of Novartis, a leading global healthcare company. Under his leadership, he has focused on advancing innovative therapies while addressing challenges in healthcare costs and access. Narasimhan advocates for sustainable practices in the pharmaceutical industry, emphasizing the need for ethical pricing of medications to ensure that life-saving treatments are accessible to all patients.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Switzerland | 3 | 6.67 | 0.28% | +20% | 8,654,622 | 28,584 | $700,000 | 2,312$ |
| Totals | 3 | 8,654,622 | 28,584 | $700,000 | 2,312$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Switzerland:
Vas Narasimhan is the CEO of Novartis and was involved in discussions regarding drug pricing with the U.S. government.
6
Switzerland:
Vas Narasimhan, CEO of Novartis, received high marks for his functional reputation among Swiss CEOs.
7
Switzerland:
Vas Narasimhan, CEO of Novartis, attended the announcement at the White House.
7
Switzerland:
Vas Narasimhan, the CEO of Novartis, is involved in discussions about drug pricing strategies.
6
Switzerland:
Vas Narasimhan is the CEO of Novartis who has also expressed concerns regarding the agreement with the US.
6
Switzerland:
Vas Narasimhan, the CEO of Novartis, tempered high expectations from the White House regarding job creation.
5
Switzerland:
Vas Narasimhan is the CEO of Novartis and assured that the negotiations with the American government are going well.
7
Switzerland:
Vas Narasimhan, the CEO of Novartis, has stated that the medication prices in Switzerland are much too low.
5
Slovenia:
Vas Narasimhan is the CEO of Novartis and is leading the company's acquisition of Avidity Biosciences.
7
Switzerland:
Vas Narasimhan is the CEO of Novartis and commented on discussions with the US government regarding price reductions.
5